Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020267 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Metastatic Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00020267: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00020267 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020267, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy.
Interventions
- DRUG Montanide ISA-51
- DRUG interleukin-2
- DRUG MAGE-12 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020267
The ClinicalTrials.gov registry entry for NCT00020267 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Montanide ISA-51 is the first listed.
NCT00020267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020267 about?
NCT00020267 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Cancer". RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy.
What is the current status of trial NCT00020267?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-07.
What interventions are being tested in trial NCT00020267?
The interventions under investigation include: Montanide ISA-51 (DRUG), interleukin-2 (DRUG), MAGE-12 peptide vaccine (DRUG).
Who is sponsoring clinical trial NCT00020267?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.